Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer.

Abstract

The efficacy and safety of toremifene-ifosfamide as a first-line chemotherapy in non-small cell lung cancer were assessed. Sixteen patients were treated with oral toremifene (420 mg on days 1-4 and 240 mg on day 5) followed by ifosfamide infusion 5 g/m2 on day 5 every 3 weeks 1-6 times. Toremifene at the doses used did not enhance the effect or toxicity of ifosfamide in previously untreated non-small cell lung cancer patients.

• Authors: E R Salomaa, K Liippo, J Ellmen, J Komi
• Journal: Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 16 Issue 1 Pg. 75-80 (Dec 1996) ISSN: 0169-5002 [Print] Ireland
• PMID: 9017586 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Toremifene
• Ifosfamide

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Drug Administration Schedule
• Drug Resistance, Multiple
• Female
• Humans
• Ifosfamide (administration & dosage)
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Prospective Studies
• Toremifene (administration & dosage)
• Treatment Outcome